Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2014 Jul 17;124(3):328-33. doi: 10.1182/blood-2014-03-561985. Epub 2014 Jun 3.

The future of autologous stem cell transplantation in myeloma.

Author information

  • 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and.
  • 2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY.


Autologous stem cell transplantation (ASCT) has long been considered frontline therapy for newly diagnosed myeloma patients. This Spotlight examines the role of ASCT in the era of novel drugs and argues that ASCT should continue to be considered for eligible patients. A combination of novel drugs with ASCT in a sequential treatment approach can attain long-term survival and perhaps cure a subset of patients. ASCT will likely remain an important platform to develop curative strategies in the foreseeable future.

© 2014 by The American Society of Hematology.

[PubMed - indexed for MEDLINE]
[Available on 2015/7/17]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk